SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:1SXP - DE000A3ENQ51 - Common Stock
14.9 EUR
-0.06 (-0.4%)
1SXP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 21 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year 1SXP was profitable.
1SXP had a positive operating cash flow in the past year.
1SXP had positive earnings in 4 of the past 5 years.
Of the past 5 years 1SXP 4 years had a positive operating cash flow.
1.2 Ratios
1SXP has a Return On Assets of 9.61%. This is amongst the best in the industry. 1SXP outperforms 90.48% of its industry peers.
1SXP's Return On Equity of 17.02% is amongst the best of the industry. 1SXP outperforms 90.48% of its industry peers.
The Return On Invested Capital of 1SXP (13.92%) is better than 90.48% of its industry peers.
1SXP had an Average Return On Invested Capital over the past 3 years of 15.68%. This is significantly above the industry average of 9.19%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROIC | 13.92% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
1.3 Margins
1SXP has a better Profit Margin (15.06%) than 80.95% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP has a better Operating Margin (19.46%) than 80.95% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
1SXP has a Gross Margin of 33.73%. This is in the lower half of the industry: 1SXP underperforms 66.67% of its industry peers.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% |
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
1SXP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
There is no outstanding debt for 1SXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
1SXP has a debt to FCF ratio of 1.72. This is a very positive value and a sign of high solvency as it would only need 1.72 years to pay back of all of its debts.
1SXP has a better Debt to FCF ratio (1.72) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that 1SXP is not too dependend on debt financing.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 90.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Altman-Z | N/A |
ROIC/WACC1.58
WACC8.82%
2.3 Liquidity
1SXP has a Current Ratio of 1.57. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
1SXP's Current ratio of 1.57 is fine compared to the rest of the industry. 1SXP outperforms 71.43% of its industry peers.
A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP's Quick ratio of 1.17 is fine compared to the rest of the industry. 1SXP outperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -2.02% in the last year.
EPS 1Y (TTM)-2.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.44%
3.2 Future
Based on estimates for the next years, 1SXP will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.92% on average per year.
Based on estimates for the next years, 1SXP will show a small growth in Revenue. The Revenue will grow by 7.94% on average per year.
EPS Next Y18.66%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
EPS Next 5Y13.92%
Revenue Next Year8.43%
Revenue Next 2Y9.34%
Revenue Next 3Y9.27%
Revenue Next 5Y7.94%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 15.36 indicates a correct valuation of 1SXP.
Based on the Price/Earnings ratio, 1SXP is valued cheaply inside the industry as 90.48% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.50, 1SXP is valued a bit cheaper.
The Price/Forward Earnings ratio is 12.94, which indicates a correct valuation of 1SXP.
1SXP's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 95.24% of the companies in the same industry.
1SXP's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.93.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.36 | ||
| Fwd PE | 12.94 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1SXP is valued cheaply inside the industry as 85.71% of the companies are valued more expensively.
1SXP's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 44.63 | ||
| EV/EBITDA | 8.58 |
4.3 Compensation for Growth
1SXP's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
1SXP has a very decent profitability rating, which may justify a higher PE ratio.
1SXP's earnings are expected to grow with 15.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y16.45%
EPS Next 3Y15.84%
5. Dividend
5.1 Amount
1SXP has a Yearly Dividend Yield of 1.21%.
The stock price of 1SXP dropped by -27.14% in the last 3 months. With lower prices the dividend yield is higher, but it may be a sign investors do not trust the long term dividend.
1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.54. 1SXP pays more dividend than 90.48% of the companies in the same industry.
1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.40% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.4%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
FRA:1SXP (12/23/2025, 7:00:00 PM)
14.9
-0.06 (-0.4%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners22.93%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.24B
Revenue(TTM)N/A
Net Income(TTM)146.90M
Analysts80
Price Target28.59 (91.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.21% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.4%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.61%
PT rev (3m)-4.36%
EPS NQ rev (1m)-4.49%
EPS NQ rev (3m)-4.49%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)-2.08%
Revenue NQ rev (1m)-0.26%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-1.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.36 | ||
| Fwd PE | 12.94 | ||
| P/S | 2.3 | ||
| P/FCF | 44.63 | ||
| P/OCF | 11.02 | ||
| P/B | 2.6 | ||
| P/tB | 2.69 | ||
| EV/EBITDA | 8.58 |
EPS(TTM)0.97
EY6.51%
EPS(NY)1.15
Fwd EY7.73%
FCF(TTM)0.33
FCFY2.24%
OCF(TTM)1.35
OCFY9.07%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)0.82
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.61% | ||
| ROE | 17.02% | ||
| ROCE | 17.02% | ||
| ROIC | 13.92% | ||
| ROICexc | 14.45% | ||
| ROICexgc | 14.86% | ||
| OM | 19.46% | ||
| PM (TTM) | 15.06% | ||
| GM | 33.73% | ||
| FCFM | 5.15% |
ROA(3y)11.06%
ROA(5y)11.96%
ROE(3y)19.55%
ROE(5y)21.48%
ROIC(3y)15.68%
ROIC(5y)17.03%
ROICexc(3y)16.18%
ROICexc(5y)17.77%
ROICexgc(3y)16.78%
ROICexgc(5y)18.78%
ROCE(3y)19.2%
ROCE(5y)20.87%
ROICexgc growth 3Y-8.59%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.46%
ROICexc growth 5YN/A
OM growth 3Y3.98%
OM growth 5YN/A
PM growth 3Y0.22%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.72 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 203.46% | ||
| Cap/Sales | 15.71% | ||
| Interest Coverage | 11.82 | ||
| Cash Conversion | 76.76% | ||
| Profit Quality | 34.23% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.17 | ||
| Altman-Z | N/A |
F-Score5
WACC8.82%
ROIC/WACC1.58
Cap/Depr(3y)291.84%
Cap/Depr(5y)279.9%
Cap/Sales(3y)17.77%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.98%
Profit Quality(5y)27.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y18.66%
EPS Next 2Y16.45%
EPS Next 3Y15.84%
EPS Next 5Y13.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%4.44%
Revenue Next Year8.43%
Revenue Next 2Y9.34%
Revenue Next 3Y9.27%
Revenue Next 5Y7.94%
EBIT growth 1Y12.08%
EBIT growth 3Y18.37%
EBIT growth 5YN/A
EBIT Next Year46.87%
EBIT Next 3Y21.99%
EBIT Next 5Y18.79%
FCF growth 1Y-27.75%
FCF growth 3Y33.55%
FCF growth 5YN/A
OCF growth 1Y-5.4%
OCF growth 3Y19.45%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 5 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 6 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 15.36 and the Price/Book (PB) ratio is 2.6.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 4 / 10 and the dividend payout ratio is 16.4%.